TLDR The new progesterone derivatives effectively inhibit 5α-reductase and bind to the androgen receptor.
The study evaluated the in vitro inhibitory activity of five new progesterone derivatives on the 5α-reductase enzyme and their antagonistic effects on the androgen receptor. The compounds showed varying IC50 values for 5α-reductase inhibition, with compound 3 being the most potent (19 nM). The Ki values indicated that compound 4 had the highest affinity for the androgen receptor, followed by compound 5, dihydrotestosterone, compound 2, compound 3, and compound 1. Overall, all five synthesized compounds were effective 5α-reductase inhibitors and exhibited affinity for the androgen receptor in the hamster prostate.
18 citations,
January 2002 in “Chemical & pharmaceutical bulletin/Chemical and pharmaceutical bulletin” New pregnane derivatives were more effective than finasteride at inhibiting a key enzyme for male pattern baldness.
22 citations,
January 2001 in “Chemical & Pharmaceutical Bulletin” Some new progesterone derivatives are better at blocking testosterone conversion than a common drug.
64 citations,
June 1995 in “Steroids” Inhibitors of the enzyme 5 alpha-reductase could potentially treat disorders like prostate cancer and baldness.
124 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene, linked to certain male health conditions, has a specific structure and low similarity to other related genes.
76 citations,
September 1992 in “Endocrinology” The human type II 5α-reductase gene has a specific structure important for understanding certain medical conditions.
193 citations,
August 1985 in “Endocrinology” Different animals have unique versions of the enzyme that changes testosterone into another hormone, which is important for creating effective treatments for prostate and hair loss conditions.
